VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer (Q38661111)

5 September 2017

title

VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer (English)

1 reference

5 September 2017

Haihong Pu

1

1 reference

5 September 2017

Qingyuan Zhang

2

1 reference

5 September 2017

Chunbo Zhao

3

1 reference

5 September 2017

Lei Shi

4

1 reference

5 September 2017

Yan Wang

5

1 reference

5 September 2017

Jingxuan Wang

6

1 reference

5 September 2017

Minghui Zhang

7

1 reference

5 September 2017

publication date

25 July 2017

1 reference

Pathology and Oncology Research

5 September 2017

published in

1 reference

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Bisphosphonates induce apoptosis in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

TWIST1 expression in breast cancer cells facilitates bone metastasis formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

affy--analysis of Affymetrix GeneChip data at the probe level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

SubpathwayMiner: a software package for flexible identification of pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

STRING v9.1: protein-protein interaction networks, with increased coverage and integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Cytoscape: a software environment for integrated models of biomolecular interaction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Performance of serological tests for syphilis in sexually transmitted diseases clinics in Guangxi Autonomous Region, China: implications for syphilis surveillance and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Interplay of VEGFa and MMP2 regulates invasion of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Role of miR-497 in VEGF-A-mediated cancer cell growth and invasion in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

VEGF-A inhibition ameliorates podocyte apoptosis via repression of activating protein 1 in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

VEGFA is necessary for chondrocyte survival during bone development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12253-017-0277-4

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/28744693

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28744693

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Breast cancer (metastatic)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28744693

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12253-017-0277-4

1 reference

5 September 2017

1 reference